News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
114,201 Results
Type
Article (8658)
Company Profile (39)
Press Release (105504)
Section
Business (32188)
Career Advice (148)
Deals (4739)
Drug Delivery (30)
Drug Development (19413)
Employer Resources (13)
FDA (4011)
Job Trends (2582)
News (61098)
Policy (7191)
Tag
Academia (535)
Africa (111)
Alabama (12)
Allergies (17)
Alliances (10216)
Alzheimer's disease (230)
Antibody-drug conjugate (ADC) (18)
Approvals (3986)
Artificial intelligence (14)
Asia (8885)
Australia (1101)
Bankruptcy (23)
Best Places to Work (2155)
Biosimilars (46)
Biotechnology (25)
Breast cancer (11)
C2C Services and Suppliers (9363)
California (450)
Canada (124)
Cancer (127)
Career advice (128)
Cell therapy (37)
China (59)
Clinical research (15369)
Collaboration (42)
Colorado (14)
COVID-19 (549)
Cystic fibrosis (11)
Data (75)
Diabetes (13)
Diagnostics (574)
Drug pricing (14)
Duchenne muscular dystrophy (12)
Earnings (10685)
Europe (16526)
Events (14506)
Executive appointments (24)
FDA (4091)
Florida (61)
Funding (25)
Gene therapy (32)
GLP-1 (101)
Government (1379)
Healthcare (2887)
Hotbed/Location (74773)
Idaho (13)
Illinois (37)
Indiana (23)
Infectious disease (553)
Inflammatory bowel disease (38)
Interviews (19)
IPO (2118)
Job creations (435)
Job search strategy (120)
Layoffs (48)
Legal (737)
Liver cancer (13)
Lung cancer (40)
Manufacturing (38)
Maryland (179)
Massachusetts (292)
Medical device (1863)
Medtech (1864)
Mergers & acquisitions (2621)
Metabolic disorders (33)
Michigan (12)
Minnesota (33)
Neuroscience (253)
New Jersey (209)
New York (125)
NextGen Class of 2024 (870)
Non-profit (478)
North Carolina (134)
Northern California (207)
Obesity (15)
Ohio (32)
Opinion (43)
Peanut (16)
Pennsylvania (94)
People (8964)
Phase I (4833)
Phase II (6442)
Phase III (5603)
Pipeline (41)
Policy (22)
Postmarket research (501)
Preclinical (1883)
Press Release (66)
Rare diseases (28)
Real estate (1001)
Regulatory (5422)
Research institute (539)
Resumes & cover letters (14)
South America (159)
Southern California (201)
Startups (669)
Texas (38)
United States (1841)
Vaccines (126)
Washington State (37)
Date
Today (40)
Last 7 days (140)
Last 30 days (447)
Last 365 days (8320)
2024 (5745)
2023 (8469)
2022 (11359)
2021 (11719)
2020 (10141)
2019 (7442)
2018 (5802)
2017 (6446)
2016 (5876)
2015 (6741)
2014 (4774)
2013 (3767)
2012 (3889)
2011 (4149)
2010 (3394)
114,201 Results for "bone biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
Bone Biologics Corporation announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device.
June 20, 2024
·
5 min read
Genetown
Bone Biologics Reports Progress With NB1 Clinical Program
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion.
March 1, 2024
·
3 min read
Deals
Bone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Corporation today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock.
March 4, 2024
·
4 min read
Genetown
Bone Biologics Announces Closing of $2.0 Million Public Offering
Bone Biologics Corporation announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share and accompanying warrant.
March 6, 2024
·
3 min read
Business
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
Bone Biologics Corporation today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.
January 11, 2024
·
3 min read
Deals
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Bone Biologics Corporation today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
January 10, 2024
·
1 min read
Genetown
Bone Biologics Announces 1-for-8 Reverse Stock Split
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.
December 18, 2023
·
3 min read
Genetown
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.
September 26, 2023
·
6 min read
Biotech Beach
Biogennix Announces Publication of a Scientific Study on Its Advanced Bone Graft Technology
Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material.
June 12, 2024
·
2 min read
Drug Development
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children’s Bone Health
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced increases in bone length while maintaining bone strength.
June 17, 2024
·
13 min read
1 of 11,421
Next
